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with advanced relapsed NSCLC (Shepherd et al. NEJM 2005;353:123-
32; Hanna et al. J Clin Oncol 2004;22:1589-97). Further required data 
were estimated from national guidelines and prescribing information 
for the drugs considered. The analysis was conducted from the perspec-
tive of German healthcare funding bodies. Cost data were obtained 
from published sources for the year 2005. Costs of medical services 
were derived from EBM 2000plus (the current physicians’ uniform fee 
scale). Drug costs in the outpatient setting were taken from the IfAP® 
Index drug price list. For hospital admissions due to AEs, the disease 
related groups for lung cancer were used. Reﬂecting the social health 
insurance (SHI) system, patient co-payments for drugs and hospital 
treatment, and the legally required discounts from pharmacists and drug 
manufacturers to the SHI system were both taken into account.
Results: The base cost per quarter per patient treated with erlotinib 
was €8,172, versus €8,055 for docetaxel and €15,870 for pemetrexed. 
Including the cost of managing AEs, the total quarterly cost per patient 
on erlotinib was €8,376, versus €9,976 for docetaxel and €16,596 for 
pemetrexed. Sensitivity analyses indicated that the difference in favour 
of erlotinib was a robust ﬁnding, being maintained across a range of 
cost conditions.
Conclusions: A comparison of total medical care costs per patient 
shows an overall cost advantage for erlotinib over docetaxel. This may 
be attributable to the favourable side effect proﬁle of erlotinib, and par-
ticularly the lack of haematological toxicity. The overall cost advantage 
for erlotinib compared with pemetrexed is a consequence of the lower 
drug costs and lower costs of AE management with erlotinib. The use 
of erlotinib for second-line therapy of NSCLC has been now shown 
to have potential health economic beneﬁts for the German healthcare 
system. 
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Impact of epidermal growth factor receptor (EGFR) pathway 
alterations on the outcome of non-small cell lung cancer (NSCLC) 
patients (pts) treated with first-line chemotherapy (CHT). 
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Background: Molecular alterations along the EGFR pathway have 
been proposed to be the major determinant of clinical outcome in 
response to EGFR tyrosine kinase inhibition in NSCLC pts. However, 
their potential impact on sensitivity to CHT has not been studied in 
detail.
Methods: Advanced NSCLC pts undergoing CHT were screened for 
EGFR gene mutations (by SSCP and sequencing) and/or increased 
copy number (by FISH), EGFR protein expression (by IHC), and HER-
2, phosphorylated AKT (pAKT), and total AKT protein expression (by 
IHC). Correlation between speciﬁc molecular alterations and clinical 
outcome (ORR, PFS, and OS) was then retrospectively explored using 
both the Cox regression model as well as classiﬁcation and regression 
trees (CART) analysis.
Results: One hundred and twenty seven pts were screened and 93 
received 1st-line CHT. The frequency of EGFR pathway alterations is 
shown in Table 1. At a median follow up of 13 mos, survival analysis 
revealed that true EGFR gene ampliﬁcation is the only signiﬁcant 
predictor of worst OS (p=0.004). No signiﬁcant correlation was 
found with PFS. ORR was signiﬁcantly worse in HER-2-positive pts 
(p=0.03). CART analysis conﬁrmed that true EGFR gene ampliﬁcation 
negatively affect OS, followed by EGFR gene mutation and chromo-
some 7 polysomy in non-ampliﬁed and non-ampliﬁed/non-mutated pts, 
respectively.
Present Absent n.e.
EGFR mutations 7 42 44
EGFR gene ampliﬁcation 10 66 17
#7 Polysomy (≥ 40%) 40 29 24
pAKT (score ≥1+) 56 15 22
EGFR (score ≥1+) 63 15 15
HER-2 (score ≥1+) 36 29 21
Conclusions: EGFR pathway alterations signiﬁcantly impact on 
outcome following 1st-line CHT for advanced NSCLC. HER-2 over-
expression negatively impacts on ORR, but not on PFS and OS. This 
information maybe useful in selecting appropriate treatment algorithm 
for advanced NSCLC pts.
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Background: Erlotinib (Tarceva®), an orally active, potent, selec-
tive inhibitor of HER1/EGFR tyrosine kinase, signiﬁcantly prolonged 
survival, delayed symptom progression, and improved quality of life 
of NSCLC patients (pts) in the BR.21 phase III placebo controlled 
trial. The multicenter, open label EAP was initiated for patients with 
advanced or metastatic NSCLC to provide erlotinib access.
Methods: Stage III/IV NSCLC pts who had failed prior chemotherapy 
or were unsuitable for chemotherapy. Eligible patients were given oral 
erlotinib (150mg/day) until disease progression or unacceptable toxic-
ity. The NCI CTC v3.o was used to evaluate toxicities. Dose reductions 
were allowed. Pts were monitored monthly.
Results: A total of 303 evaluable pts were enrolled in 15 centers, in 12 
months. The analysis was done on 194 pts, who represent 64% of the 
303 pts enrolled in TRUST in Israel. Patient characteristics: median 
age 67 years (range 37-86); male 62%, female 38%; caucasian 97%, 
black 0%, other 1%, no data 2%; ECOG PS0 13%, PS1 42%, PS2 
28%, PS3 16%, no data 1%; Stage IIIB 10%, Stage IV 88%, no data 
2%; Adenocarcinoma 45%, BAC 7%, LCC 6%, SCC 15%, Other 28%; 
Prior chemotherapy: 1st line 23%, 2nd line 45%, 3rd line 28%, other 
4%; Non-smoker 28%, Former or Current-smoker 72%, no data 1%. As 
expected, rash was a common AE mainly mild or moderate:G1 and/or 
2- 49%, G3 and/or 4 9%. Other G3-4 SAE included: diarrhea <1%; 
fatigue 3%; dehydration 1%; urticaria 1%; dyspnea 2%. 17% of pts 
required dose reduction. Dose reductions to 100mg occurred in 14%, 
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and to 50mg in 3% of pts. The reasons for dose reduction were mainly 
rash 54%, diarrhea 19.4%, pruritus 9.7%; rash and diarrhea 6.5%. 
Conclusions: Based on a large number of unselected pts with advanced 
NSCLC in Israel, the safety data obtained from the interim results 
with erlotinib conﬁrm the favorable safety proﬁle of erlotinib previ-
ously observed in clinical trials. To date, the results show erlotinib 
to be generally well tolerated, thus allowing most pts to receive the 
recommended daily dose of 150mg. Efﬁcacy data may be available by 
September 2007.
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Background: The addition of bevacizumab (B) to chemotherapy 
improves survival in patients (pts) with previously untreated metastatic 
NSCLC. The addition of bevacizumab to erlotinib (E) appears promis-
ing in second line therapy of NSCLC. Bevacizumab plus erlotinib 
(B+E) has never been tested in 1st line NSCLC. 
Methods: Eligible pts with previously untreated stage IIIB (pleural 
effusion) or stage IV NSCLC and normal organ function without 
hemoptysis or brain metastasis were treated with B (15mg/kg every 21 
days) plus E (150mg once daily) for 4 cycles (cycle- 21 days) followed 
by B (15mg/kg), carboplatin (AUC 6) and paclitaxel (200 mg/m2) every 
21 days for 4 cycles. Pts who did not progress on initial B+E received 
maintenance therapy with B+E until progression.
Results: We have enrolled 40 pts (of 48 planned) in this ongoing study. 
The characteristics: 25 male, 15 female; median age 70 years; 37 stage 
IV, 3 stage IIIB; 3 never smokers; 26 adenocarcinoma, 10 non-small 
cell lung cancer not otherwise speciﬁed, 3 undifferentiated carcinoma, 
1 adenocarcinoma with BAC; performance status 0 in 16 and 1 in 
24. Twenty three pts have completed 4 cycles of B+E with 5 partial 
responses (22%), 13 stable disease (56%) and 5 progressive disease 
(22%). Sixteen pts have completed bevacizumab plus chemotherapy 
with best responses of 5 partial response (31%), 9 stable disease (56%), 
2 progressive disease (12%). Of the 11 pts treated with maintenance 
B+E, 4 developed progressive disease and have discontinued therapy. 
The median number of cycles received during maintenance therapy 
with B+E was 6 (range 2-15+). Treatment related toxicities: related to 
B+E- grade 3 rash (3 pts), grade 3 fatigue (2 pts), and grade 3 epistaxis 
(1 pt); related to B and chemotherapy- grade 3 neuropathy (2 pts), 
grade 3 hypersensitivity reaction (1 pt), grade 4 neutropenia (2 pts), 
and grade 4 arterial thrombosis (1 pt). Most notably, there have been no 
major bleeding episodes so far. 
Conclusions: 1. The combination of B+E achieved a disease control 
rate of 78% in previously untreated patients with IIIB/IV NSCLC and 
is well tolerated. 2. The initial administration of 4 cycles of B+E does 
not impair the efﬁcacy platinum based doublet chemotherapy with 
bevacizumab.
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Serum E-cadherin does not associate with response to gefitinib in 
patients with non-small cell lung cancer (NSCLC)
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Background: The epidermal growth factor receptor (EGFR) is ex-
pressed in many human epithelial malignancies, including NSCLC. The 
response rates to EGFR tyrosine kinase inhibitors (TKIs) in unselected 
NSCLC patients rages from 9-27%. NSCLC cell lines highly sensitive 
to EGFR TKIs express E-cadherin. Patients with high E-cadherin ex-
pression in tumors samples have improved time-to-progression (TTP) 
after treatment with EGFR TKI erlotinib, indicating the signiﬁcant role 
of epithelial-mesenchymal transition (EMT) to predict sensitivity/re-
sistance to EGFR inhibitors. These results suggest that high E-cadherin 
expression would be a clinically relevant biomarker for patient’s selec-
tion to EGFR TKI therapy. The aim of the present study was to investi-
gate the potential association between serum E-cadherin expression and 
clinical activity of geﬁtinib in European NSCLC patients. 
Methods and Results: Serum E-cadherin levels were evaluated by 
ELISA using commercially available kit (R&D Systems). Statistical 
evaluation was performed by Kaplan-Meier analysis and a Cox pro-
portional hazard model. Among 135 consecutive patients treated with 
geﬁtinib (median age, 67 years; 75% males; 83% ever smokers), 123 
were evaluable for response, TTP and overall survival (OS). Forty-four 
(36%) had stable disease (SD) and 15 (13%) had objective response 
(OR). Serum E-cadherin levels ranged from 15 to 203 ng/mL with a 
median value of 30 ng/mL. The whole population was divided into two 
groups based on median E-cadherin levels (< 30 versus ≥ 30 ng/mL). 
Higher serum E-cadherin level was observed in patients with older age 
(P=.003), ECOG PS of 2 versus 0 or 1 (P=.027), and squamous cell 
histology (P=.045).
The response rates were 13% and 11% in patients with low and high 
E-cadherin level, respectively (P=.809); disease control rates were 52% 
and 44% respectively (P=.415). Median TTP and OS were 3.5 and 5.8 
months, and 3 and 7 months, in patients with low and high E-cadherin 
levels (P=.245; P=.434 respectively). 
Conclusions: These results indicate that higher E-cadherin levels are 
associated with age, advanced PS and squamous cell histology. Serum 
E-cadherin does not appear to predict response, TTP, and OS in patients 
with NSCLC after therapy with geﬁtinib. Corresponding E-cadherin 
tissue studies are ongoing.
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Background: Two case reports describe a response to E after failure of 
G (Garﬁeld DH, J Clin Oncol 2005) or to G after failure of E (Choong 
NW et al, Nat Clin Pract Oncol 2006) in patients (pts) with advanced 
NSCLC. Otherwise, a limited experience in 5 pts suggests that E is not 
